, Volume 41, Issue 2, pp 321–328 | Cite as

Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii

  • M. H. Rigatto
  • V. B. Ribeiro
  • D. Konzen
  • A. P. Zavascki
Clinical and Epidemiological Study



This study was designed to compare the efficacy of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT) by Pseudomonas aeruginosa or Acinetobacter baumannii.


A prospective cohort study was performed. Patients >18 years of age with the diagnosis of VAP or VAT who received appropriate therapy for >48 h were analyzed. The primary outcome was 30-day mortality. Clinical covariates were assessed and compared between the groups.


A total of 67 episodes were analyzed: 45 (67 %) treated with polymyxin B and 22 (33 %) with comparators. The crude 30-day mortality was 53 % (24 of 45) in the polymyxin B group and 27 % (6 of 22) in the comparator group (P = 0.08). Multivariable analysis using Cox regression models indicated that polymyxin B treatment was independently associated with increased mortality.


Polymyxin B treatment in the currently recommended dosage may be inferior to other drugs in the treatment of VAP and VAT caused by organisms tested as susceptible in vitro to this agent.


Pseudomonas aeruginosa Acinetobacter baumannii Polymyxin B Colistin Ventilator-associated pneumonia 


  1. 1.
    Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis. 2010;51(Suppl 1):S59–66.PubMedCrossRefGoogle Scholar
  2. 2.
    American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRefGoogle Scholar
  3. 3.
    Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8:71–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006–09). J Antimicrob Chemother. 2011;66:2070–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Zavascki AP, Li J. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infect Dis. 2008;8:403–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60:1206–15.PubMedCrossRefGoogle Scholar
  7. 7.
    Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother. 2011;66:175–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008;61:1369–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65:1019–27.PubMedCrossRefGoogle Scholar
  10. 10.
    Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47:1298–304.PubMedCrossRefGoogle Scholar
  11. 11.
    Clinical Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; 19th informational supplement (M100-S19). Wayne, PA.Google Scholar
  12. 12.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–803.PubMedCrossRefGoogle Scholar
  16. 16.
    Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65:2231–7.PubMedCrossRefGoogle Scholar
  18. 18.
    El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med. 2008;178:513–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Kiem S, Schentag JJ. Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia. J Chemother. 2010;22:103–9.PubMedGoogle Scholar
  20. 20.
    Zavascki AP, Li J, Nation RL, Superti SV, Barth AL, Lutz L, et al. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J Clin Microbiol. 2009;47:3064–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • M. H. Rigatto
    • 1
  • V. B. Ribeiro
    • 2
  • D. Konzen
    • 3
  • A. P. Zavascki
    • 4
  1. 1.Infectious Diseases ServiceHospital São Lucas da Pontifícia Universidade Católica do Rio Grande do SulPorto AlegreBrazil
  2. 2.Laboratory of MicrobiologyHospital de Clínicas de Porto AlegrePorto AlegreBrazil
  3. 3.School of MedicinePontifícia Universidade Católica do Rio Grande do SulPorto AlegreBrazil
  4. 4.Infectious Diseases ServiceHospital de Clínicas de Porto AlegrePorto AlegreBrazil

Personalised recommendations